Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06912165RecruitingPhase 2
WD-890 for moderate to severe plaque psoriasis
This study tests an investigational drug called WD-890 for people with moderate-to-severe plaque psoriasis that hasn't responded well enough to other treatments. It may help reduce skin patches, scaling, and itching.
Nanjing, JiangsuAges 18–70 - NCT07207954RecruitingPhase 1
Testing LFD-200 in healthy adults and adults with rheumatoid arthritis
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
MelbourneAges 18–75 - NCT06926192Recruiting
Secukinumab plus surgery for moderate to severe hidradenitis suppurativa
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
Nanjing, JiangsuAges Up to 80 years - NCT06837922RecruitingPhase 3
Study of MG-K10 for moderate to severe asthma
This trial tests a new drug called MG-K10 for people with moderate to severe asthma that is not well controlled with current treatments. It aims to see if the drug can reduce asthma attacks and improve breathing. You may be able to join if you have had asthma for at least a year, use high-dose inhalers plus another controller medicine, and have had a recent flare-up.
Guangzhou, GuangdongAges 12–75 - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Chandler, ArizonaAges 12 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chandler, ArizonaAges 18 years+ - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Scottsdale, ArizonaAges 18–80 - NCT07185009RecruitingPhase 3
Testing duvakitug for long-term ulcerative colitis control
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Tucson, ArizonaAges 16–80 - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Peoria, ArizonaAges 16–80 - NCT07184944RecruitingPhase 3
Study of Duvakitug for moderate to severe Crohn's disease
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
Colorado Springs, ColoradoAges 16–80 - NCT07189806Recruiting
Asthma study tracking symptoms over 5 years
This study follows adults with mild, moderate, or severe asthma to better understand the condition. You'll attend regular check-ups at the clinic to monitor your lung function and symptoms over five years.
LondonAges 18 years+ - NCT07192146Recruiting
Patient experiences after dental emergency treatment
This study looks at how patients feel after receiving emergency dental treatment for tooth pain. It aims to understand what factors affect their recovery and satisfaction.
BangkokAges 18 years+ - NCT07192016RecruitingPhase 4
MRI study of triple inhaler for COPD with breathlessness
This study uses a special MRI scan to see how well a single triple inhaler works for people with COPD who have moderate to severe shortness of breath or feel their health is not good. It compares two groups: those with a low risk of flare-ups and those with a high risk, to find out if the treatment helps both groups.
London, OntarioAges 50–85 - NCT07183761RecruitingPhase 2
Stem cell therapy for diabetic nerve pain
This study tests whether umbilical cord stem cells can help people with diabetic nerve damage in their legs who haven't gotten enough relief from standard treatments. It aims to improve symptoms like numbness, pain, and tingling.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT07180277RecruitingPhase 4
Steroid treatment for moderate to severe brain injury
This trial tests a steroid medicine called methylprednisolone to see if it can help people who have had a moderate to severe brain injury. It aims to reduce swelling in the brain and possibly improve recovery.
Suzhou, JiangsuAges 18–65 - NCT07180511Enrolling by invitationPhase 3
A study of QY201 tablets for moderate to severe eczema
This trial tests a new pill called QY201 for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. It aims to see if QY201 can help control itching and skin inflammation.
Hangzhou, ZhejiangAges 18–75 - NCT07177911RecruitingPhase 1
Study of CC312 for moderate to severe lupus
This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
Chengdu, SichuanAges 18–65 - NCT05819463Recruiting
Study care for moderate to severe atopic dermatitis
This trial looks at treatment and medical care for teens and adults with moderate to severe atopic dermatitis (eczema). It may help by testing ways to manage symptoms better based on severity and current treatment needs.
BaselAges 12 years+ - NCT07170917RecruitingPhase 2
Testing a new drug for moderate to severe hidradenitis suppurativa
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
Phoenix, ArizonaAges 18 years+ - NCT07165002RecruitingPhase 1
Study of LY3537031 in people with and without liver problems
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
KistarcsaAges 18–85 - NCT07161960Recruiting
Early vs. delayed gallbladder removal after drainage
This trial compares removing the gallbladder early (within a few days) versus waiting several weeks after a drainage tube is placed. It aims to find the best timing for surgery in people with moderate to severe gallbladder inflammation.
Chiang MaiAges 20 years+ - NCT07152366RecruitingPhase 4
Hormone and tetuzumab for active thyroid eye disease
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07146269Enrolling by invitation
Virtual reality and brain stimulation for depression
This study tests if combining virtual reality with a gentle brain stimulation method at home can help people with major depression. You would use a headset and small electrodes to receive treatment in your own home.
MunichAges 18–65
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.